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Endothelin-1 (ET-1) dose-dependently increased HIF1a expression in pulmonary artery smooth
muscle cells (PASMCs). Inhibition of protein synthesis did not affect ET-1-induced HIF1a expression.
The maximum effect of ET-1 was similar to that caused by proteasome inhibitor MG132. Further
study indicates that ET-1 also dose-dependently stimulated calcineurin activation, speciﬁc calcineu-
rin inhibitor cyclosporine A (CsA), abolished ET-1-induced HIF1a elevation, and reversed ET-1-
induced RACK1 (receptor of activated protein kinase C 1) de-phosphorylation. Endothelin receptor
A was found to speciﬁcally mediate the effects of ET-1. To examine whether RACK1 is particularly
involved in proteasome-dependent HIF1a degradation, RACK1 was silenced by siRNA transfection.
Cells lacking RACK1 exhibited signiﬁcant elevation of HIF1a protein level. Taken together, our study
suggests that ET-1 suppressed proteasome-dependent HIF1a degradation by calcineurin-dependent
RACK1 de-phosphorylation.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Increased production of endothelin-1 (ET-1) in pulmonary vas-
culature has been found to mediate the development of a variety of
types of pulmonary hypertension [1,2]. Mechanisms underlying
ET-1 causing pulmonary hypertension consist: (i) stimulation of
pulmonary vasoconstriction by elevating intracellular calcium
[3–5]; (ii) induction of pulmonary vascular remodeling by stimu-
lating pulmonary artery smooth muscle cells (PASMC) proliferation
[5,6] and triggering matrix metalloproteinase (MMP) production/
secretion [7]. The important role of ET-1 in pulmonary hyperten-
sion has been further conﬁrmed by the successful treatment of
such diseases with ET-1 receptor blocker in both clinic patients
and animal models [8,9].
In the development of hypoxic pulmonary hypertension, over-
generation of ET-1 is mediated by hypoxia inducible factor (HIF)
in endothelium and smooth muscle cells [10,11]. HIF is a highly
conserved transcriptional factor expressed in oxygen-breathing
species [12,13]. HIF is a heterodimer composed of alpha (HIFa)chemical Societies. Published by E
eases Research Center, The
Jiaotong University, No. 157,and beta (HIFb) subunits. HIFb is constitutively expressed in cells,
while, under normoxic condition, HIFa is hydroxylated by HIF pro-
lyl-hydroxylase, The ‘‘proline’’ hydroxylated form of HIFa is recog-
nized by von Hippel–Lindau (VHL) tumor suppressor protein as
part of a complex with E3 ubiquitin ligase which makes HIFa a tar-
get for degradation by an E3 ubiquitin ligase, leading to quick deg-
radation by proteasome [12,13]. It has been shown that hypoxia
increases HIFa stability and therefore HIF activity by reactive
oxygen species (ROS)-induced activation of calcium–calmodulin
kinase (CamK) and protein kinase C (PKC) [14,15]. Recent studies
have suggested that hypoxia-independent mechanisms are in-
volved in the regulation of HIFa expression and activity, and recep-
tor of activated protein kinase C 1 (RACK1) mediates this process
[12,16]. While it is unclear whether this mechanism exists in pul-
monary vascular system, where HIF plays an important role in the
pathogenesis of pulmonary hypertension.
In this study, we found a novel mechanism whereby ET-1 in-
creased HIFa protein expression by activation of calcineurin and
subsequent de-phosphorylation of RACK1 in PASMCs under non-
hypoxic condition, this further increased HIF activity and drove
PASMCs to produce and secrete a variety of bioactive mediators
including ET-1 to participate in the development of pulmonary
hypertension. Our study implies that, between ET-1 and HIF, alsevier B.V. All rights reserved.
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mote smooth muscle cell contraction and proliferation and con-
tribute to the development of pulmonary hypertension.
2. Materials and methods
2.1. Cell preparation and culture
Primary smooth muscle cells from pulmonary artery were pre-
pared from Sprague–Dawley rats (125–250 g) as described before
[17]. Cells were cultured in Dulbecco’s Modiﬁed Eagle Medium
(DMEM, Invitrogen) with 10% fetal bovine serum (FBS), 100 U/ml
penicillin, and 100 lg/ml streptomycin in a 37 C, 5% CO2 humidi-
ﬁed incubator. Cells were passaged by trypsinization using 0.05%
trypsin/EDTA (Invitrogen). All experiments were performed using
cells between passages 4 and 8. To test the purity of smooth mus-
cle cells, cells were stained with 40,60-diamidino-2-phenylindole
(DAPI, Invitrogen) and FITC labeled anti-smooth muscle a-actin
antibody (Sigma) for nucleus and smooth muscle actin, respec-
tively. Fluorescence microscope images indicated that cells con-
tained more than 93% of smooth muscle cells (data not shown
here). Before each experiment, cells were incubated in 0.5%
FBS–DMEM for 24 h to minimize serum-induced effect on cells.
Endothelin-1 was purchased from Peptides International.
Cyclosporin A (CsA) was applied as calcineurin inhibitor (Sigma).
Cycloheximide (CHX) was obtained from Calbiochem.
2.2. Immunoprecipitation and immunoblotting
Cells were lysed in 50 mM Tris–HCl, pH 7.4, 1% Nonidet P-40
(NP-40), 0.1% sodium dodecyl sulfate (SDS), 150 mM NaCl, 0.5%HIF1α  
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Fig. 1. Effects of ET-1 on HIF1a expression and transactivation. (A) PASMCs were treated
using immune blotting. GAPDH was used as loading control (n = 5 each group). (B) PASM
synthesis inhibitor cycloheximide for 15–60 min. Protein level of HIF1a was examined u
HIF1a protein level between control and ET-1-stimulated cells. PASMCs were treated with
level of HIF1a was examined with immune blotting (n = 5 each group). (D) PASMCs were
ET-1 for another 24 h, luciferase activity of cell lysates was examined (n = 5 each groupsodium-deoxycholate, 1 mM EDTA, 1 mM phenylmethylsulfonyl
ﬂuoride (PMSF), 1 mM Na3VO4, 1 mM NaF, and proteinase inhibi-
tors. Lysates were centrifuged at 13,000 rpm at 4 C for 15 min
and supernatant was collected as total protein. Protein concentra-
tion was determined with a BCA protein assay kit (Pierce, Inc). Two
hundred microgram protein was applied for immunoprecipitation
using RACK1 antibody and protein A/G agarose. Protein was sepa-
rated on SDS–PAGE gel and transferred onto Trans-Blot nitrocellu-
lose membrane (Bio-Rad). Polyclone antibodies against HIF1a (cell
signaling technology) and phosphoserine (Abcam), monoclone
antibody against glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were used following manufacturer protocols. Horseradish
peroxidase-conjugated goat anti-rabbit or goat anti-mouse IgG
were used as secondary antibody (Sigma). Reactions were devel-
oped with SuperSignal West Pico Chemiluminescent Substrate
(Pierce, Inc) and exposure to autoradiographic ﬁlm. Signaling was
quantiﬁed from scanned ﬁlms using Scion NIH Image software
(Scion).
2.3. Calcineurin activity assay
Cells were lysed in 400 ml lysis buffer containing 50 mM Tris,
pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.2% Nonidet P-40, 1 mM
DTT, and protease inhibitor cocktail. Samples were centrifuged at
10,000g for 10 min at 4 C. The supernatant was collected and
loaded to a chromatography column (BioMol) to remove the free
phosphate from the extract. The elutes from the column was col-
lected and the protein concentration was measured with a BCA
protein assay kit (Pierce). Calcineurin activity was determined
using calcineurin assay kit (BioMol). Samples (20 lg of elutes)
were incubated with 0.15 mM RII substrate for 30 min, at 30 C 
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sing western blot (n = 5 each group). (C) Proteasome inhibitor MG132 equalized the
MG132 (10 lM) for 4 h and followed by ET-1 stimulation (100 nM) for 24 h, protein
transfected with HIF-responsive luciferase plasmid for 24 h, and then treated with
). ⁄P < 0.01 versus control (Con).
3890 M. Li et al. / FEBS Letters 586 (2012) 3888–3893in 2 assay buffer (100 mM Tris, pH 7.5, 200 mM NaCl, 12 mM
MgCl2, 1 mM DTT, 0.05% NP-40, 1 mM CaCl2, 250 nM calmodulin,
500 nM okadaic acid), or in 2 EGTA buffer (100 mM Tris, pH
7.5, 20 mM EGTA, 200 mM NaCl, 12 mM MgCl2, 1 mM DTT, 0.05%
NP-40, 500 nM okadaic acid). Released free phosphate was de-
tected on a micro-plate reader at OD 620 nM based on the classic
malachite green assay. The difference in free phosphate released
from reactions in assay buffer or in EGTA buffer indicates speciﬁc
calcineurin activity. All samples were run in quadruplicate and a
mean value was calculated.
2.4. siRNA transfection
To silence the expression of RACK1 protein, PASMCs were trans-
fected with sequence-speciﬁc or non-targeting control siRNA
(Dharmacon) using Lipofectamine™ 2000 reagent (Invitrogen).
Brieﬂy, cells were cultured until they reached 30–40% conﬂuence,
siRNA and Lipofectamine were diluted in serum-free DMEM sepa-
rately and incubated for 5 min at room temperature. siRNA was
mixed with Lipofectamine and incubated at room temperature
for 20 min. Then, the complex of siRNA and Lipofectamine was
added into cells and cells were cultured for 48 h at 37 C, 5% CO2
in a humidiﬁed incubator. Effects of siRNA transfection were ana-
lyzed using western blots.C
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Fig. 2. Effects of ET-1 on calcineurin activation and RACK1 phosphorylation. (A) PASMCs
applied for analyzing the activity of calcineurin using calcineurin assay kit (n = 5 each
treatment of cells with speciﬁc calcineurin inhibitor cyclosporine A (CsA, 10 lM) for 30
agarose beads, and then probed with anti-phosphor-serine and anti-RACK1 antibody (n =
ET receptor inhibitor bosentan (10 lM) or PD155080 (100 nM) for 30 min, calcineurin a
⁄P < 0.01 versus control, #P < 0.01 versus ET-1-stimulated cells.2.5. HIF-responsive luciferase plasmid transfection and luciferase
activity assay
HIF-responsive luciferase construct (Qiagen) encodes the ﬁreﬂy
luciferase reporter gene under the control of a minimal (m) CMV
promoter and tandem repeats of the hypoxia transcriptional re-
sponse element (HRE). PASMCs were transfected using lipofect-
amine. Brieﬂy, cells were cultured until they reached 80–90%
conﬂuence. Plasmid and Lipofectamine™ 2000 reagent (Invitro-
gen) were diluted in serum-free DMEM separately and incubated
for 5 min at room temperature and then mixed together and incu-
bated for 20 min at room temperature. Next, the complex of plas-
mid and Lipofectamine was added to cells, and the cells were
cultured for 48 h at 37 C, 5% CO2 in a humidiﬁed incubator.
HIF-responsive luciferase activity was measured using a luciferase
Assay Kit (Roche Diagnostics Corporation), according to the
instructions of the manufacturer.
2.6. Statistics
Values are presented as mean ± S.D. Difference between multi-
ple groups were compared by analysis of variance (ANOVA) fol-
lowed by a Tukey’s multiple comparisons test. P < 0.05 was
considered to represent signiﬁcant difference between groups. p-RACK1
RACK1
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were stimulated with different concentration of ET-1 for 30 min, cell lysates were
group). (B) PASMCs were treated with 100 nM ET-1 for 24 h with or without prior
min. Cell lysates were immuneprecipitated with RACK1 antibody and protein A/G
5 each group). (C and D) PASMCs were stimulated with 100 nM ET-1 with or without
ctivity (C) and phosphorylation of RACK1 (D) were determined (n = 5 each group).
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3.1. Effects of endothelin-1 on HIF1a expression and transactivation
ET-1 is a 21-amino-acid peptide synthesized and secreted pre-
dominantly by vascular endothelial cells and smooth muscle cells
and plays a critical role in the development of pulmonary hyper-
tension [2]. ET-1 is one of the major targets transactivated by
HIF. Hypoxia-induced ET-1 expression is initiated when HIFa sub-
unit is stabilized and activated in response to lack of oxygen [12].
ET-1 binds to its receptors on pulmonary vascular smooth muscle
cells causing pulmonary vasoconstriction and stimulating the pro-
liferation of vascular smooth muscle cells to contribute to the
development of pulmonary hypertension [12]. ET-1 secreted from
pulmonary vascular system can active particularly signaling cas-
cades to modulate a bunch of genes expression/activity in pulmon-
ary vascular smooth muscle cells [18–21], however, it is unclear
whether HIF is regulated by ET-1 in a hypoxia-independent way
in PASMCs. In this study, we examined whether ET-1 increases
HIF1a expression in PASMCs. Cells were treated with different con-
centration of ET-1 for 24 h, expression of HIF1a was determined
using immunoblotting. Fig. 1A shows that ET-1 dose-dependently
increased HIF1a protein level, a 3.06-fold increase was achieved
with 100 nM ET-1 (P < 0.01 versus control). To determine whether
elevated HIF1a expression was due to its increased synthesis or
decreased degradation, cells were stimulated with ET-1 for 24 h
and followed by addition of 10 lM protein synthesis inhibitorHIF1α  
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Fig. 3. Calcineurin/RACK1 mediates ET-1-induced HIF1a accumulation. (A) PASMCs were
speciﬁc calcineurin inhibitor cyclosporine A (CsA, 10 lM) for 30 min. HIF1a was examine
Primary cultured PASMCs were transfected with RACK1 sequence-speciﬁc siRNA and no
with antibodies against RACK1 and GAPDH (loading control) (n = 5 each group). (C) Prima
cells were lysed and HIF1a protein level was determined with immune blotting (n = 5 ecycloheximide for 15–60 min. Fig. 1B indicates that addition of
protein synthesis inhibitor after ET-1 stimulation did not signiﬁ-
cantly reduce HIF1a protein level. Next, PASMCs were pre-treated
with speciﬁc proteasome inhibitor MG132 (10 lM for 4 h) and fol-
lowed by ET-1 stimulation. Fig. 1C shows that MG132 equalized
HIF1a protein level between control and ET-1 treated cells. Above
results suggest that ET-1 induces HIFa expression not by increas-
ing its protein synthesis but by inhibiting its degradation.
To examine the effect of ET-1 on transcriptional activity of
HIF1a, PASMCs were ﬁrst transfected with HIF1-responsive lucifer-
ase plasmid for 24 h, and then treated with ET-1 for another 24 h,
luciferase activity of cell lysates were examined. Fig. 1D shows that
ET-1 dose-dependently increased luciferase activity, 100 nM ET-1
induced a 2.9-fold increase in luciferase activity compared with
control (P < 0.01), suggesting that ET-1 effectively transcriptional
activates HIF1a in PASMCs.
3.2. Effects of endothelin-1 on calcineurin activity and RACK1
phosphorylation
It has been shown that ET-1 increases intracellular calcium by
triggering calcium release from intracellular store and stimulating
calcium inﬂux through voltage-gated Ca2+ channels in pulmonary
vascular smooth muscle cells [22]. Calcium as a second messenger
of cell can further activate several signaling pathways, such as
calcineurin [23]. Here, we determined whether ET-1-induced ele-
vation of intracellular calcium activates calcineurin in PASMCs.RACK1
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cell lysates were applied for measuring calcineurin activity. As
shown in Fig. 2A, ET-1 dose-dependently increased calciuneurin
activity, 100 nM ET-1 caused a 3-fold increase in calcineurin activ-
ity compared with control (P < 0.01), indicating that calcineurin is
effectively activated in PASMCs by ET-1. This is consistent with the
ﬁnding by de Frutos et al. [24], who has reported that ET-1 acti-
vates calcineruin/NFAT signaling pathway in pulmonary arteries.
To examine whether ET-1-induced calcineurin activation
de-phosphorylates RACK1, PASMCs were stimulated with 100 nM
ET-1 for 24 h with or without pre-incubation of cells with CsA
(10 lM for 30 min). RACK1 was immunoprecipitated from whole
cell lysates using RACK1 antibody and protein A/G agarose beads,
and then probed with anti-phosphoserine antibody. Fig. 2B shows
that ET-1 dramatically suppressed the basal level of phosphoryla-
tion of RACK1, pretreatment of cells with CsA restored serine
phosphorylation of RACK1 despite the presence of ET-1, indicating
that activation of calcineurin apparently de-phosphorylates RACK1
in PASMCs.
ET-1 binds to its receptors and activates a variety of signaling
cascades. Two subtypes of endothelin receptor have been identi-
ﬁed, ET-A and ET-B receptor. To determine which type receptor
speciﬁcally mediates the effects of ET-1 here, we applied both dual
ET receptor antagonist bosentan (10 lM) and selective ET-A recep-
tor antagonist PD155080 (100 nM) before (30 min) and during the
stimulation of PASMCs with ET-1. Fig. 2C and D indicate that both
bosentan and PD155080 fully blocked the effects of ET-1 on calci-
neurin activation and RACK de-phosphorylation, suggesting that
endothelin receptor A particularly mediates the above effects.
3.3. Role of calcineurin and RACK1 on endothelin-1-induced HIF1a
accumulation
To investigate whether ET-1-triggered calcineurin activation is
involved in the HIF1a accumulation, PASMCs were pre-treated
with selective calcineurin inhibitor CsA and followed by ET-1 stim-
ulation, the protein level of HIF1a was analyzed using immuno-
blotting. Fig. 3A shows that prior treatment of cells with CsA
(10 lM) for 30 min dramatically reduced ET-1-induced HIF1a pro-
tein elevation, which dropped from 3.2- to 1.5-fold increase over
control in CsA-treated cells (P < 0.01), suggesting that calcineurin
speciﬁcally mediates the effect of ET-1 on increasing HIF1a
accumulation.
It has been reported that RACK1 competes with HSP90 binding
to HIFa and mediates O2- and prolyl-hydroxylase/VHL-
independent ubiquitination and proteasomal degradation of HIFa
in several non-vascular smooth muscle cell lines [25]. Recent study
has further suggested that calcineurin binds to and de-phosphory-
lates RACK1 at Ser146within dimerization domain preventing HIFa
degradation by ubiquitin proteasome system [26]. To determine the
speciﬁcity of RACK1 in modulation of proteasome-dependent
HIF1a degradation in PASMCs, we ﬁrst utilized siRNA to silence
the expression of RACK1, and then HIF1a protein level was
examined. Fig. 3B indicates that sequence-speciﬁc siRNA transfec-
tion reduced RACK1 protein level to 25 percent of control
(P < 0.01), non-targeting siRNA did not affect RACK1 protein level.
Cells lacking RACK1 by siRNA transfection demonstrated a 3.4-fold
increase in HIF1a protein level (P < 0.01 versus control, Fig. 3C),
suggesting that RACK1 particularly mediates the degradation of
HIF1a, and de-phosphorylation of RACK1 by calcineurin suppresses
the function of RACK1 on facilitating the degradation of HIF1a.
4. Conclusion
The present study indicates that ET-1 post-transcriptionally in-
duces HIF1a expression by suppressing proteasome-dependentHIF1a degradation, this effect is coupled to ET-1/ETA receptor-
triggered calcineurin activation and subsequent RACK1 de-phos-
phorylation. Our study also implies that there may be a positive
feedback loop between ET-1 and HIF1a to contribute to the devel-
opment of pulmonary hypertension.Acknowledgments
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